NCT06250244 2024-12-11
177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase 1/2 Unknown
Clinical Trials
1,078 trialsNCT03310632 2024-09-25
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer
Golden Biotechnology Corporation
Phase 1/2 Unknown
NCT05830097 2024-08-26
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Coherent Biopharma (Hefei) Co., Ltd.
Phase 1/2 Unknown
NCT05832892 2024-06-14
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 1/2 Unknown
NCT03275493 2024-05-28
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT04029181 2024-05-03
ImmunoPET With an Anti-CD8 Imaging Agent
University Medical Center Groningen
Phase 1/2 Unknown
NCT06395337 2024-05-02
MIRCA & MIPAC
Radboud University Medical Center
Phase 1/2 Unknown
NCT06308406 2024-04-11
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
NCT06195189 2024-03-25
WU-KONG36
Sichuan University
Phase 1/2 Unknown
NCT06328387 2024-03-25
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Unknown
NCT03024489 2024-03-15
Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma
Mahidol University
Phase 1/2 Unknown
NCT04903873 2024-03-15
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Eutilex
Phase 1/2 Unknown
NCT03975907 2024-03-12
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
CARsgen Therapeutics Co., Ltd.
Phase 1/2 Unknown
NCT05111860 2024-03-07
Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy
Shanghai Minimally Invasive Surgery Center
Phase 1/2 Unknown
NCT04601584 2024-03-06
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
AO GENERIUM
Phase 1/2 Unknown
NCT05370547 2024-03-06
Chidamide Bridging for CAR-T Therapy
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT06237413 2024-03-06
A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Unknown
NCT04780217 2024-03-04
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
ImmVira Pharma Co. Ltd
Phase 1/2 Unknown
NCT06106139 2024-03-04
Ketogenic Diet Improves Thrombocytopenia in Cancer Patients
Fujian Medical University
Phase 1/2 Unknown
NCT03643549 2024-02-29
BORTEM-17
Haukeland University Hospital
Phase 1/2 Unknown
NCT04330820 2024-02-28
RELAX
Technische Universität Dresden
Phase 1/2 Unknown
NCT05033925 2024-02-28
Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients
Gadjah Mada University
Phase 1/2 Unknown
NCT06279767 2024-02-28
Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Unknown
NCT03576378 2024-02-26
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 1/2 Unknown
NCT05574881 2024-02-26
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
Fudan University
Phase 1/2 Unknown
NCT05575804 2024-02-26
GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
Fudan University
Phase 1/2 Unknown
NCT01754402 2024-02-20
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
Phase 1/2 Unknown
NCT04934514 2024-02-20
Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 1/2 Unknown
NCT05991518 2024-02-20
IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 1/2 Unknown
NCT02730923 2024-02-13
VICTORIA
Centre Leon Berard
Phase 1/2 Unknown
NCT06255262 2024-02-13
Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
China Medical University, China
Phase 1/2 Unknown
NCT04984668 2024-02-09
A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors
Suzhou Kintor Pharmaceutical Inc,
Phase 1/2 Unknown
NCT05842317 2024-02-09
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT06074029 2024-02-08
Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT05358379 2024-02-07
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown
NCT04358393 2024-02-01
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT06237400 2024-02-01
A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Unknown
NCT03789097 2024-01-30
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Unknown
NCT05675605 2024-01-30
A Study of TY-1091 in Patients With Advanced Solid Tumors
TYK Medicines, Inc
Phase 1/2 Unknown
NCT05278975 2024-01-26
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
RS Oncology LLC
Phase 1/2 Unknown
NCT04983810 2024-01-25
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown
NCT06223308 2024-01-25
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT06223646 2024-01-25
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Phase 1/2 Unknown
NCT06221774 2024-01-24
Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2 Unknown
NCT05186012 2024-01-23
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT05576961 2024-01-23
Safety and Efficacy of RX-af01 Combined With PD-1 Antibody
Sun Yat-sen University
Phase 1/2 Unknown
NCT06218771 2024-01-23
A Study of TQB3454 Tablets in Patients With Blood Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT05464173 2024-01-22
CINDERELLA
Fudan University
Phase 1/2 Unknown
NCT04284228 2024-01-16
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
NexImmune Inc.
Phase 1/2 Unknown
NCT05906524 2024-01-10
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
Shanghai Kanda Biotechnology Co., Ltd.
Phase 1/2 Unknown